B+
Bull case
25%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
PGNY
ProgynyCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 revenue rose 5.3% to $350.5 million, gross margin expanded to 25.5%, and adjusted EBITDA reached $62.1 million. Management reported favorable early selling-season commitments, offering a path to renewed growth if launches and engagement follow through [#SEC-8K-2026-08-06].
Posture
Mixed
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-10-26.
What can break
A previously lost large client complicates year-over-year comparisons, and future large-account retention remains consequential [#SEC-8K-2026-08-06].
Momentum
67
Value
61
Sentiment
45
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $27.00 · Bull $35.00 · Bear $19.00Analysis 2026-09-30; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $34.42
Why
Momentum67 · Δ7d +11.8
Value61 · Δ7d +0.2
Sentiment45 · Δ7d -9.7
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-10-26.
- • Value remains the lead driver in the composite, 7D delta +0.2.
Contradictions & invalidation
- • A previously lost large client complicates year-over-year comparisons, and future large-account retention remains consequential [#SEC-8K-2026-08-06].
- • ART cycles were nearly flat year over year in Q2 despite growth in covered members; utilization and treatment mix remain important tests [#SEC-8K-2026-08-06].
- • Q2 ART cycles were roughly flat year over year, while management's third-quarter outlook assumes a more pronounced summer slowdown.
Catalyst clock
2026-12-29
Full-year guidance delivery
Lead driver: Value · See fundamentals
Momentum
67
8% active weight
Current posture
7d trendFlat
Δ7d
+11.8
Δ21d
+24.3
Value
61
47% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.8
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-9.7
Δ21d
-24.9
Why this grade
Composite grade C. Momentum 67.3 / Value 60.9 / Sentiment 45.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-30. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$2.16B
Beta
0.96
Shares Out
76.73M
P/E (TTM)
42.7
P/S (TTM)
1.81
P/FCF (TTM)
11.88
Rev YoY
+5.3%
EPS YoY
+78.9%
Gross Margin
+24.6%
Op Margin
+8.6%
Net Debt
-$282.37M
Current Ratio
2.14
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data